Search | Clinical Trials Finder

Conditions: Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Drug · Procedure · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 391
States / cities: Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 291 more

Conditions: Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
Interventions: azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Questionnaire Administration, Stereotactic Radiosurgery; Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
Interventions: Magnetic Resonance Imaging, Prophylactic Cranial Irradiation; Procedure · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 428
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more

Conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Solid Tumor
Interventions: questionnaire administration, survey administration, quality-of-life assessment; Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 366 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Limited-Stage Small Cell Lung Cancer
Interventions: HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI); Drug · Radiation
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 31
States / cities: Arcadia, California • Los Alamitos, California • Los Angeles, California + 26 more

Conditions: Lung Cancer
Interventions: laboratory biomarker analysis; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,060 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non Small Cell Lung Cancer
Interventions: Nivolumab, Cisplatin, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Carboplatin, Paclitaxel, Ipilimumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 57
States / cities: Glendale, Arizona • Los Angeles, California • Denver, Colorado + 48 more

Conditions: Lung Cancer, Pulmonary Complications
Interventions: educational intervention, supervised exercise program; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 60
States / cities: Fort Collins, Colorado • Decatur, Illinois • Maywood, Illinois + 32 more

Conditions: Lung Cancer
Interventions: cisplatin, etoposide, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2010
U.S. locations: 242
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 189 more

Conditions: Early Stage Non-small Cell Lung Cancer, Non-small Cell Lung Cancer
Interventions: Computed tomography-guided stereotactic adaptive radiotherapy, ETHOS; Radiation · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dysphagia, Lung Cancer, Pain, Esophagitis
Interventions: Manuka honey in liquid form, Manuka honey in lozenge form, Standard supportive care; Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 59
States / cities: Mobile, Alabama • San Francisco, California • Stanford, California + 50 more

Conditions: Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions: Nicotine Replacement Patch; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Lung Cancer
Interventions: SBRT 40.0 Gy, SBRT 42.5 Gy, SBRT 45.0 Gy, SBRT 47.5 Gy, SBRT 50.0 Gy, SBRT 52.5 Gy, SBRT 55.0 Gy, SBRT 57.5 Gy, SBRT 60.0 Gy; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 57
States / cities: Peoria, Arizona • Scottsdale, Arizona • Burbank, California + 50 more

Conditions: Non Small Cell Lung Cancer
Interventions: Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay, Pembrolizumab, Platinum Doublet Chemotherapy; Diagnostic Test · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: trastuzumab; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Small-cell Lung Cancer, SCLC, Small Cell Lung Cancer Limited Stage
Interventions: Hippocampal-sparing Prophylactic Cranial Irradiation; Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Non-Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: Precision Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 7
States / cities: Birmingham, Alabama • Stuart, Florida • Louisville, Kentucky + 3 more

Conditions: Anorexia, Cachexia, Lung Cancer
Interventions: megestrol acetate, radiation therapy; Drug · Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Non-small Cell Lung Cancer
Interventions: Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 29
States / cities: Fresno, California • Glendale, California • Irvine, California + 22 more

Conditions: Lung Cancer
Interventions: fenretinide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Detroit, Michigan

Conditions: Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer, Stage II Lung Cancer, Stage III Lung Cancer
Interventions: Cisplatin, Carboplatin, Etoposide, Pembrolizumab, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Radiation Therapy; Drug · Biological · Procedure + 1 more
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lung Cancer
Interventions: comparative genomic hybridization, fluorescence in situ hybridization, gene expression analysis, microarray analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry, medical chart review, diagnostic bronchoscopy; Genetic · Other · Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 689 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2016
U.S. locations: 4
States / cities: Nashville, Tennessee

Conditions: Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions: 3-Dimensional Conformal Radiation Therapy, Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Etoposide, Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration; Radiation · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 533
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 401 more

Search by objective public record fields.

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Family Quality of Life Among Families With a Member Who is a Cancer Patient

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Studying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung Cancer

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer

Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer

Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer

Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients

Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer

Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease

Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer

Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)